Therapeutic Asset Ratings
6,371 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Toripalimab
Triple-Negative Breast Carcinoma
Nanjing Leads Biolabs Co.,Ltd
P3
BB
(64)
TRASTUZUMAB
Gastric / Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital
P3
BB
(64)
TRASTUZUMAB
Gastroesophageal Adenocarcinoma
UNICANCER
P3
BB
(64)
Zilovertamab
Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
P3
BB
(64)
Basiliximab
Acute Lymphoblastic Leukemia
City of Hope Medical Center
P2
BB
(64)
Basiliximab
Hodgkins Lymphoma
City of Hope Medical Center
P2
BB
(64)
Basiliximab
Myelodysplastic Syndrome
City of Hope Medical Center
P2
BB
(64)
Cetuximab
Colorectal Adenocarcinoma
Bayer
P2
BB
(64)
Durvalumab
Colorectal Carcinoma
Gruppo Oncologico del Nord-Ovest
P2
BB
(64)
Durvalumab
Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer Center
P2
BB
(64)
IMMUNOGLOBULIN G1, ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN MONOCLONAL MEDI9447 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI9447 .LAMBDA.-CHAIN, DIMER
Pancreatic Adenocarcinoma
M.D. Anderson Cancer Center
P2
BB
(64)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Triple-Positive Breast Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P2
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Acute Leukemia
SWOG Cancer Research Network
P2
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
B-Cell Neoplasm
Curis, Inc.
P2
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
OHSU Knight Cancer Institute
P2
BB
(64)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
T-Cell Acute Lymphoblastic Leukemia
University of Washington
P2
BB
(64)
Ivonescimab
Metastatic Malignant Neoplasm
Revolution Medicines, Inc.
P2
BB
(64)
Lorigerlimab
Castration-Resistant Prostate Carcinoma
MacroGenics
P2
BB
(64)
Nivolumab
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
BB
(64)
Nivolumab
Diffuse Large B-Cell Lymphoma
David Bond, MD
P2
BB
(64)
Nivolumab
Neuroblastoma
Instituto do Cancer do Estado de São Paulo
P2
BB
(64)
Nivolumab
Pancreatic Adenocarcinoma
Mayo Clinic
P2
BB
(64)
Nivolumab
Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
P2
BB
(64)
Nivolumab
Refractory Malignant Neoplasm
CatalYm GmbH
P2
BB
(64)
Obinutuzumab
Mantle Cell Lymphoma
National Cancer Institute (NCI)
P2
BB
(64)
Showing 501 to 525 of 6,371 assets
Previous
Page 21 of 255
Next